# Safety of BBC1501 Intravitreal Injection in Patients With Neovascular Age-Related Macular Degeneration (nAMD)

> **NCT05803785** · PHASE1 · RECRUITING · sponsor: **Benobio Co., Ltd.** · enrollment: 18 (estimated)

## Conditions studied

- Age-Related Macular Degeneration

## Interventions

- **DRUG:** BBC1501

## Key facts

- **NCT ID:** NCT05803785
- **Lead sponsor:** Benobio Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-01
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05803785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05803785, "Safety of BBC1501 Intravitreal Injection in Patients With Neovascular Age-Related Macular Degeneration (nAMD)". Retrieved via AI Analytics 2026-08-02 from https://api.ai-analytics.org/clinical/NCT05803785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*